Dr. Reddy's Pioneers Pharma Advancements Through Strategic Partnerships and Innovation: A Glimpse into Vision 2030: Growth Trajectory and Opportunities for Indian Pharma
In a recent contribution to the Citeline CEO Conclave's white paper on "Vision 2030: Growth Trajectory and Opportunities for Indian Pharma," Kalpeshkumar N. Modi, Vice President and Regional Sales Head at Dr. Reddy's Laboratories, highlighted the company's strategic moves towards innovation and collaboration in the pharmaceutical industry.
During the challenging times of the Covid-19 pandemic, Dr. Reddy's actively pursued in-licensing and partnering opportunities, demonstrating substantial momentum. Notable collaborations include agreements with Eli Lilly for baricitinib, MSD for Molnupiravir, and, more recently, partnerships with Chinese company Pregene for an anti- BCMA CAR-T cell therapy injection designed for multiple myeloma. Additionally, the company entered into agreements with Wellington Zhao Tai Therapies for an exclusive license to its CAR-T cell technology.
Dr. Reddy's commitment to expanding its therapeutic portfolio is evident in in-licensing deals with Jiangsu Hengrui Pharmaceuticals Co., Ltd for a breast cancer therapy called pyrotinib, and with Shanghai Junshi Biosciences Co. Ltd. to develop and commercialise toripalimab, an anti-PD-1 monoclonal antibody, across 21 countries. The company's B2B initiatives focus on fostering direct partnerships to support big pharma in product lifecycle management and collaborating with smaller companies engaged in drug development under the 505(b)(2) approval process.
Known for its leadership in digitisation efforts to enhance productivity and foster continuous improvement, Dr. Reddy's is also capitalising on CDMO opportunities. The company's subsidiary, Aurigene Pharmaceutical Services, is dedicated to discovery, development, and manufacturing for global R&D-driven biopharma companies. This involves building value-added partnerships, such as those aimed at developing cell and gene therapies, reducing the cost of CAR T-cell therapy, and innovating therapeutic solutions.
“We are continuing to work toward strengthening our position as a partner of choice,” said Kalpeshkumar N. Modi, Vice President, and Regional Sales Head of Dr. Reddy’s Laboratories.
White Paper Link - https://bit.ly/3uMkwfJ